一种治疗评估工具，用于监测吸入性阿佐霉素赖氨酸在囊性纤维化中的真实世界疗效。
A treatment evaluator tool to monitor the real-world effectiveness of inhaled aztreonam lysine in cystic fibrosis.
机构信息
Cork Adult Cystic Fibrosis Centre, University College Cork, Cork University Hospital, Cork, Ireland.
Belfast Adult Cystic Fibrosis Centre, Belfast City Hospital, Belfast, UK.
出版信息
J Cyst Fibros. 2017 Nov;16(6):695-701. doi: 10.1016/j.jcf.2017.02.006. Epub 2017 Apr 6.
BACKGROUND
Studies are required that evaluate real-world outcomes of inhaled aztreonam lysine in patients with cystic fibrosis (CF).
METHODS
Our treatment-evaluator tool assessed the effectiveness of inhaled aztreonam in routine practice in 117 CF patients across four time periods (6-12 (P2) and 0-6months (P1) pre-initiation, and 0-6 (T1) and 6-12months (T2) post-initiation). Outcomes were: changes in %-predicted forced expiratory volume in 1s (FEV), body-mass index (BMI), hospitalisation days and intravenous antibiotic usage.
RESULTS
Median FEV% predicted for each 6-month period was 38.9%, 34.6%, 37.1% and 36.5%; median change was -2.0% between P2 and P1, increasing to +0.6% (p<0.001) between P1 and T1. Annualised hospital bed-days was reduced (p=0.05) post-initiation, as was intravenous antibiotics days (p=0.001). BMI increased over 6months post-initiation (p≤0.001).
CONCLUSIONS
In patients with CF in routine practice, inhaled aztreonam lysine is associated with improved lung function and weight, and reduced hospitalisation and intravenous antibiotic use.
背景
需要研究评估囊性纤维化（CF）患者吸入氨曲南赖氨酸的真实世界结局。
方法
我们的治疗评估工具评估了吸入氨曲南在四个时间段（起始前 6-12 个月（P2）和 0-6 个月（P1）以及起始后 0-6 个月（T1）和 6-12 个月（T2））在 117 例 CF 患者中的常规实践中的有效性。结果为：1 秒用力呼气量（FEV）预计百分比、体重指数（BMI）、住院天数和静脉使用抗生素的变化。
结果
每个 6 个月期间的中位 FEV%预测值分别为 38.9%、34.6%、37.1%和 36.5%；中位变化为 P2 和 P1 之间为-2.0%，P1 和 T1 之间增加至+0.6%（p<0.001）。起始后，年住院天数减少（p=0.05），静脉用抗生素天数减少（p=0.001）。起始后 6 个月内 BMI 增加（p≤0.001）。
结论
在常规实践中，CF 患者使用吸入氨曲南赖氨酸与改善肺功能和体重以及减少住院和静脉使用抗生素有关。
Zotero 插件